Novo Nordisk A/S Common Stock (NY:NVO)

Despite a challenging year, the company has a lot to look forward to in the coming years.

What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? ↗

Today 15:25 EST

The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.

Is Oral Wegovy a Game Changer for Novo Nordisk? ↗

Today 15:05 EST

Arctic Chill: Global Markets Reeling as Trump Demands Greenland Purchase with Massive Tariff Threats

Today 10:53 EST

WASHINGTON D.C. / NEW YORK — Global financial markets were plunged into a state of "Arctic uncertainty" this Tuesday, January 20, 2026, as U.S. stock futures cratered following a weekend of...

Novo Nordisk A/S-Spons ADR (NYSE:NVO) Demonstrates a Strong Dividend Profile Backed by High Profitability ↗

January 19, 2026

Via Chartmill

The Arctic Gambit: Trump’s National Security Push for Greenland Sparks Diplomatic Crisis and Market Volatility

January 19, 2026

In a move that has sent shockwaves through both the halls of the United Nations and the trading floors of Wall Street, President Donald Trump has officially designated the acquisition of Greenland as a...

In the opening weeks of 2026, the artificial intelligence industry has moved beyond general-purpose models to a high-stakes "verticalization" phase, with healthcare emerging as the primary...

Topics Economy Electric Vehicles Government

The Battle for the White Coat: OpenAI and Anthropic Reveal Dueling Healthcare Strategies

January 19, 2026

Via TokenRing AI

Topics Artificial Intelligence

NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’ ↗

January 16, 2026

AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly ↗

January 14, 2026

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗

January 14, 2026

January 13, 2026

Anthropic’s New Specialized Healthcare Tiers: A New Era for AI-Driven Diagnostics and Medical Triage

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗

January 19, 2026

Via MarketBeat

Topics ETFs

January 19, 2026

On January 11, 2026, Anthropic, the AI safety and research company, officially unveiled its most significant industry-specific expansion to date: specialized healthcare and life sciences tiers for its...

Via TokenRing AI

Topics Artificial Intelligence

The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins

January 19, 2026

As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin...

Via Finterra

Topics Economy

The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature

January 19, 2026

As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its...

Via Finterra

Topics Artificial Intelligence Bankruptcy Economy

Prediction: 2026 Will Be the Year of Eli Lilly ↗

January 19, 2026

A catalyst lies just ahead.

WASHINGTON D.C. — In a dramatic escalation of his "America First" foreign policy, President Donald Trump has moved beyond mere interest to a formal demand for the acquisition of Greenland, threatening...

The Arctic Ultimatums: Trump’s Greenland Bid Sparks Global Trade War and NATO Crisis

January 16, 2026

The choice isn't that hard.

Topics Economy Government World Trade

Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? ↗

January 16, 2026

NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares? ↗

January 16, 2026

The United Kingdom’s Medicines and Healthcare products Regulatory Agency on Friday announced that it had approved a maximum dose of up to 7.2 milligrams a week for Novo’s Wegovy earlier this month.

Novo Nordisk A/S (NYSE:NVO) shares are trading lower on Thursday after the company was hit with a lawsuit from compounding pharmacy Strive Specialties.

Novo Nordisk Stock Dips As Company Faces GLP-1 Antitrust Lawsuit ↗

January 15, 2026

Via Benzinga

Topics Lawsuit

Eli Lilly’s $1.2 Billion Acquisition of Ventyx Biosciences: Bridging the Gap Between Weight Loss and Chronic Inflammation

January 15, 2026

In a bold move to solidify its dominance in the cardiometabolic market, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, that it has entered into a definitive agreement to acquire Ventyx...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive Specialties

Topics Intellectual Property

Eli Lilly Stock Slips After Antitrust Lawsuit Against GLP-1 Providers ↗

January 15, 2026

Via Benzinga

Topics Lawsuit

Slimmer Waistlines, Fatter Margins: Jefferies Says Airline Companies Will Profit From America’s Weight-Loss Boom ↗

January 14, 2026

Healthcare Sector Stages Resilient Rebound as Policy Clarity and GLP-1 Innovations Fuel Investor Optimism

January 14, 2026

The U.S. healthcare sector has entered 2026 on a remarkably strong footing, staging a decisive rebound after a tumultuous 2025. This resurgence is being driven by a rare alignment of legislative...

What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?

Topics Earnings Economy

Is It Time to Dump Your Shares of Eli Lilly? ↗

January 14, 2026

For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a...

Topics Intellectual Property

Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns ↗

January 13, 2026

Via MarketBeat

The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound

January 13, 2026

Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...

Topics Artificial Intelligence Economy Intellectual Property

Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance

January 13, 2026

Via PredictStreet

Topics Economy Intellectual Property

Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? ↗

January 13, 2026

Both companies now aim to win in the oral weight loss drug market.

The gap may be too hard to close in the next 12 months.

Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? ↗

January 13, 2026